{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:25Z","timestamp":1790644465731,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle Cell Lymphoma International Prognostic Index (MIPI) score, high proliferation index, p53 deletions and\/or mutations, complex karyotype, minimal residual disease, and several others. However, using these prognostic factors to guide treatment selection has largely remained elusive. Given the heterogeneous behavior of this disease and varying patient characteristics, we suggest that the time has come for a more risk-adapted approach to this disease. In this article, we review the numerous prognostic factors that have been described for MCL, both at the time of diagnosis and following first-line treatment. We then propose a risk-adapted approach to first-line therapy for MCL, which would reserve intensive therapy for the highest risk patients and spare others excessive toxicity.<\/jats:p>","DOI":"10.3390\/jpm12071134","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:06:00Z","timestamp":1657749960000},"page":"1134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?"],"prefix":"10.3390","volume":"12","author":[{"given":"Lindsay","family":"Hammons","sequence":"first","affiliation":[{"name":"Department of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: A retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: A population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood.V87.10.4358.bloodjournal87104358","article-title":"Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: A comparison with the Working Formulation","volume":"87","author":"Pittaluga","year":"1996","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"911.e1","DOI":"10.1016\/j.jtct.2021.08.014","article-title":"Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Man-tle Cell Lymphoma","volume":"27","author":"Riedell","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era","volume":"37","author":"Gerson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2020","journal-title":"HemaSphere"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","article-title":"Ki-67 expression level histological subtype and the International Prognostic","volume":"69","author":"Joensuu","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00019606-200303000-00005","article-title":"Cell cycle altera-tions in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lym-phoma (MCL) and MCL-BV","volume":"12","author":"Hofmann","year":"2003","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prog-nostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell trans-plantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: A Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Klapper","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic hypermutation and V(H) gene usage in mantle cell lymphoma","volume":"68","author":"Thorselius","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","article-title":"Cellular morigin of human B-cell lymphomas","volume":"341","author":"Hansmann","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjh.15519","article-title":"Validation of the MCL35 gene expression proliferation assay in randomized trials of the Euro-pean Mantle Cell Lymphoma Network","volume":"184","author":"Mottok","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study","volume":"105","author":"Ferrero","year":"2019","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-018-0728-4","article-title":"Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma","volume":"20","author":"Condoluci","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of trans-formed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","article-title":"miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MI-PI-B prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic value of FDG-PET in patients with mantle cell lymphoma: Results from the LyMa-PET Project","volume":"105","author":"Bailly","year":"2020","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","article-title":"FDG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome","volume":"30","author":"Karam","year":"2009","journal-title":"Nucl. Med. Commun."},{"key":"ref_49","first-page":"1633","article-title":"Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group","volume":"37","author":"Touzeau","year":"2010","journal-title":"Eur. J. Pediatr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Noring, K., Carlsten, M., Sonnevi, K., and Wahlin, B.E. (2021). The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: A population-based study showing improved outcome. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08225-5"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.semnuclmed.2017.09.004","article-title":"PET\/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up","volume":"48","author":"Karls","year":"2018","journal-title":"Semin. Nucl. Med."},{"key":"ref_56","unstructured":"K\u00fcppers, R. (2019). Flow cytometric MRD detection in selected mature B-cell malignancies. Lymphoma: Methods and Protocols, Humana Press."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: A technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"key":"ref_58","first-page":"509","article-title":"Measurement of circulating tumor DNA to guide management of patients with lymphoma","volume":"17","author":"Sriram","year":"2019","journal-title":"Measurement"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: Final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial","volume":"38","author":"Hoster","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission","volume":"22","author":"Cowan","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2018","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hon.2550","article-title":"Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance","volume":"36","author":"Klener","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood-2019-129323","article-title":"Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) \u00b1 Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"106605","DOI":"10.1016\/j.leukres.2021.106605","article-title":"Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis","volume":"108","author":"Wu","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.13649","article-title":"Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival","volume":"107","author":"Shanmugasundaram","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/10428194.2018.1455973","article-title":"Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma","volume":"59","author":"Calzada","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:49:30Z","timestamp":1760140170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jpm12071134"],"URL":"https:\/\/doi.org\/10.3390\/jpm12071134","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}